Search results
General guidelines for the treatment of women with von Willebrand disease at delivery. Since pregnant women with VWD are at increased risk of postpartum hemorrhage if untreated 9, 17, 27, 31, treatment options should be planned at the beginning of pregnancy.
- Table 1
Given the wide heterogeneity of phenotypes and of the...
- Mcmdm-1Vwd
Introduction. von Willebrand factor (VWF) is a multimeric...
- Table 1
May 20, 2019 · The variable pattern of changes observed during pregnancy of von Willebrand factor (VWF) and factor VIII (FVIII), the protein carried by VWF, prompts a careful evaluation of pregnant women with VWD to plan the most appropriate treatment at the time of parturition.
- Giancarlo Castaman, Paula D. James
- 2019
Oct 26, 2021 · Even though von Willebrand disease has no cure, treatment can help prevent or stop bleeding episodes. Your treatment depends on: The type and severity of your condition
May 1, 2017 · During pregnancy, hormonal influences lead to an increase in vWF and clotting factors VII, VIII, and X while anticoagulant factors (such as protein S) decrease, shifting hemostasis to a procoagulant state to compensate for anticipated hemorrhage during parturition. 3 Although vWF and FVIII levels rise and peak during the third trimester, women w...
- Caroline Berube, Brian Dietrich
- 2017
Current Approaches to Pregnancy and Childbirth in Women With von Willebrand Disease – Hematology & Oncology. Clinical Advances in Hematology & Oncology. April 2018 - Volume 16, Issue 4. Current Approaches to Pregnancy and Childbirth in Women With von Willebrand Disease. Jill M. Johnsen, MD. Associate Member. Bloodworks Northwest.
Oct 26, 2021 · Symptoms & causes. Diagnosis & treatment. Doctors & departments. On this page. Overview. Symptoms. When to see a doctor. Causes. Risk factors. Complications. Prevention. Overview. Von Willebrand disease is a lifelong bleeding disorder in which your blood doesn't clot properly.
Jan 1, 2022 · von Willebrand disease (VWD) disproportionately affects women because of the potential for heavy menstrual bleeding (HMB), delivery complications, and postpartum hemorrhage (PPH). To systematically synthesize the evidence regarding first-line management of HMB, treatment of women requiring or desiring neuraxial analgesia, and management of PPH.
